Zhitong Finance App News, Zaiding Pharmaceutical (09688) announced today the first data from a global phase 1b clinical study evaluating zocilurtatug pelitecan (zoci, formerly ZL-1310) combined with atilizumab (with or without carboplatin) for first-line treatment of extensive small cell lung cancer (ES-SCLC). The data will be presented at the European Society of Medical Oncology (ESMO) 2026 conference in Madrid, Spain.

“Despite continuous advances in treatment methods, extensive small cell lung cancer is still an extremely destructive disease. Many patients progress within about five months of starting standard first-line treatment.” Dr. Rafael G. Amado, president of Zaiding Pharmaceuticals and head of global research and development, said. “The confirmed high remission rates and the encouraging long-lasting and well-tolerated safety features we observed in this standard regimen without chemotherapy are particularly outstanding. We believe that zoci combines efficacy and safety, and is expected to become the preferred ADC cornerstone drug for small cell lung cancer, including in combination with immunotherapy. We are preparing to launch a global phase 3 study of the zoci combined immuno-oncology (IO) treatment regimen and continue to evaluate the potential of zoci in combination with T-cell connectors and immuno-oncology therapies.”

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.